Handok introduced Actelion’s pulmonary hypertension therapy, ‘Opsumit’

Handok(President Young-jin Kim) launched a new Actelion’s pulmonary hypertension therapy, ‘Opsumit Tab 10mg(generic name: macitentan, hereinafter referring to Opsumit),’ in Korea.

After launching ‘Tracleer’ developed by Actelion, a innovative new drug development company at Switzerland, Handok has also be able to take charge in the domestic marketing and sales of its next product, ‘Opsumit.’